Overactive Bladder (OAB) Therapeutics - Pipeline Assessment and Market Forecasts to 2019

Report Summary

GlobalData, the industry analysis specialist, has released its new report, "Overactive Bladder (OAB) Therapeutics - Pipeline Assessment and Market Forecasts to 2019". The report is an essential source of information and analysis on the global Overactive Bladder Therapeutics market. The report identifies the key trends shaping and driving the global Overactive Bladder Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Overactive Bladder Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData's team of industry experts.

Scope

The report provides information on the key drivers and challenges of the Overactive Bladder Therapeutics market. Its scope includes -

• Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Overactive Bladder Therapeutics market revenues data from 2006 to 2010, forecast for nine years to 2019.
• Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
• Analysis of the current and future competition in the seven key countries Overactive Bladder Therapeutics market.
• Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
• Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Overactive Bladder Therapeutics market.
• Analysis of key recent licensing and partnership agreements in Overactive Bladder Therapeutics market

Reasons to buy

The report will enhance your decision making capability. It will allow you to -

• Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
• Develop business strategies by understanding the trends shaping and driving the global Overactive Bladder Therapeutics market.
• Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Overactive Bladder Therapeutics market in future.
• Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
• Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
• Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
• What's the next big thing in the global Overactive Bladder Therapeutics market landscape? - Identify, understand and capitalize.

More Info

The OAB Therapeutics Market is Forecast to Decline up to 2019

GlobalData estimated the global Overactive Bladder (OAB) therapeutics market to be worth $1.8 billion in 2011. However, it is expected to decline to $1.3 billion by 2019 at a Compound Annual Growth Rate (CAGR) of (4.3%). This decline is primarily attributable to the patent expiries of key drugs in the OAB therapeutics market such as Oxytrol, Enablex/Esmelex (darifenacin), Toviaz (fesoterodine), Ditropan/Ditropan XL (oxybutynin), Detrol/Detrol LA (tolterodine) and VESIcare (solifenacin). Whilst there will be an increase in population and the launch of new products (Anturol Gel and YM178) during this period, they are insufficient to negate the impact of the aforementioned patent expiries. The market remains well-served with the current marketed products, most of which are moderately efficacious in their respective target areas but weak safety profiles are a concern.

Current Treatment Options Leave Moderate level of Unmet Need

At present the OAB therapeutics market is made up of drugs such as Enablex/Esmelex (darifenacin), Toviaz (fesoterodine) Detrol (tolterodine), VESIcare (solifenacin), Sanctura XR (trospium), Ditropan XL (oxybutynin) and Botox, which all possess moderate efficacy profiles, but the inability of these drugs to offer absolute patient compliance, patient satisfaction and drug safety leaves an unmet need in the market. The low patient compliance of the currently marketed drugs is due to their limited efficacy and the adverse effects associated with them. The currently marketed drugs all possess similar profiles in terms of their mechanisms of action, safety and efficacy. Therefore, there is scope for new products with novel mechanisms of action which also provide better safety and efficacy profiles. The entry of such products would have a significant impact on the future OAB therapeutics market. .

A Weak Pipeline is Unlikely to Contribute to the OAB Therapeutics Market during the Forecast period

The OAB therapeutics developmental pipeline has 32 molecules in various phases of clinical and preclinical development. There are five molecules in late-stage New Drug Application (NDA filed and Phase III) development. Although, there are 10 first-in-class molecules (FIC) in the OAB pipeline, only one (YM178) is in the NDA filing stage. The launch of YM178 is expected to increase the valuation of the OAB therapeutics market. It is yet to be seen if and by how much it will increase patient compliance and adherence, which is an important unmet need in the OAB therapeutics market. The rest of the FIC molecules are in early phases of development and are not expected to have any impact on the OAB therapeutics market during the forecast period (2011- 2019). There is still significant untapped potential within the market as the currently available therapies do not provide sufficient comfort to the needs of patients. The market is demanding new entrants with novel treatments and therapy designs to improve the overall patient and physician satisfaction levels.

Table of Contents

1 Table of Contents
1.1 List of Tables 5
1.2 List of Figures 6

2 Overactive Bladder (OAB) Therapeutics - Introduction
2.1 Overview 7
2.2 Epidemiology 7
2.3 Signs and Symptoms 7
2.4 Etiology 8
2.5 Pathophysiology 8
2.5.1 Storage Phase 8
2.5.2 Voiding Phase 8
2.6 Diagnosis of OAB 10
2.6.1 Examination of Medical History 10
2.6.2 Physical Examination 10
2.6.3 Urodynamic Tests 10
2.6.4 Cough Stress Test 10
2.6.5 Voiding Cystourethrogram 10
2.7 Treatment and Management Pattern 11
2.7.1 Non-Pharmacological Treatment 11
2.7.2 Pharmacological 11
2.7.3 Specialized therapy 12
2.8 GlobalData Pipeline Report Guidance 13

3 Overactive Bladder (OAB) Therapeutics - Market Characterization
3.1 Overview 14
3.2 OAB Therapeutics Market Size (2006-2011) – Global 14
3.3 OAB Therapeutics Market Forecast (2011-2019) – Global 17
3.4 OAB Therapeutics Market Size (2006-2011) – The US 20
3.5 OAB Therapeutics Market Forecast (2011-2019) – The US 21
3.6 OAB Therapeutics Market Size (2006-2011) – France 23
3.7 OAB Therapeutics Market Forecast (2011-2019) – France 24
3.8 OAB Therapeutics Market Size (2006-2011) – Germany 26
3.9 OAB Therapeutics Market Forecast (2011-2019) – Germany 27
3.10 OAB Therapeutics Market Size (2006-2011) – Italy 29
3.11 OAB Therapeutics Market Forecast (2011-2019) – Italy 30
3.12 OAB Therapeutics Market Size (2006-2011) – Spain 32
3.13 OAB Therapeutics Market Forecast (2011-2019) – Spain 33
3.14 OAB Therapeutics Market Size (2006-2011) – The UK 35
3.15 OAB Therapeutics Market Forecast (2011-2019) – The UK 36
3.16 OAB Therapeutics Market Size (2006-2011) – Japan 38
3.17 OAB Therapeutics Market Forecast (2011-2019) – Japan 39
3.18 Drivers and Barriers for the OAB Therapeutics Market 40
3.18.1 Drivers for the OAB Therapeutics Market 40
3.18.2 Barriers for the OAB Therapeutics Market 40
3.19 Key Events Impacting the Future Market 41
3.20 Opportunity and Unmet Need 42
3.21 Key Takeaway 43

4 Overactive Bladder (OAB) Therapeutics - Competitive Assessment
4.1 Overview 44
4.2 Strategic Competitor Assessment 44
4.3 Product Portfolio for the Major Marketed Products in the OAB Therapeutics Market 45
4.3.1 Botox (onabotulinumtoxinA) 45
4.3.2 Detrol/Detrol LA (tolterodine tartrate) 46
4.3.3 Ditropan XL (Oxybutynin chloride) 47
4.3.4 Enablex (darifenacin) 48
4.3.5 Sanctura XR (trospium chloride) 50
4.3.6 Toviaz (fesoterodine fumarate) 50
4.3.7 VESIcare (solifenacin succinate) 52
4.4 Key Takeaway 52

5 Overactive Bladder (OAB) Therapeutics - Pipeline Assessment
5.1 Overview 53
5.2 Strategic Pipeline Assessment 53
5.3 OAB Pipeline – Pipeline by Phases of Development 53
5.3.1 OAB Therapeutics – Pre-registration Pipeline 54
5.3.2 OAB Therapeutics – Phase III Pipeline 54
5.3.3 OAB Therapeutics – Phase II Pipeline 55
5.3.4 OAB Therapeutics – Phase I Pipeline 55
5.3.5 OAB Therapeutics – Preclinical Pipeline 56
5.4 OAB Pipeline by Mechanism of Action 56
5.5 OAB Technology Trends Analytical Framework 57
5.6 OAB Therapeutics – Promising Drugs under Clinical Development 59
5.7 Molecule Profile for Promising Drugs under Clinical Development 59
5.7.1 Anturol Gel (oxybutynin) 59
5.7.2 DR-3001 (oxybutynin vaginal ring) 60
5.7.3 HOB-294 (oxybutynin transdermal patch) 60
5.7.4 YM178 (mirabegron) 61
5.8 Key Takeaway 61

6 Overactive Bladder (OAB) Therapeutics – Clinical Trials Mapping
6.1 Clinical Trials by Country (US, EU5 and Japan) 62
6.2 Clinical Trials by Phase 63
6.3 Clinical Trials by Trial Status 64
6.4 Overall Sponsors 65
6.5 Prominent Sponsors 66
6.6 Top Companies Participating in OAB Therapeutics Clinical Trials 67

7 Overactive Bladder (OAB) Therapeutics - Strategic Assessment
7.1 Future Market Competition Scenario 68

8 Overactive Bladder (OAB) Therapeutics - Future Players
8.1 Introduction 69
8.2 Allergan, Inc. 69
8.2.1 Company Overview 69
8.2.2 Financial Overview 69
8.2.3 Business Description 70
8.2.4 OAB Therapeutics Pipeline 70
8.3 Antares Pharma, Inc. 71
8.3.1 Company Overview 71
8.3.2 Financial Overview 71
8.3.3 OAB Therapeutics Pipeline 71
8.4 Astellas Pharma Inc. 71
8.4.1 Company Overview 71
8.4.2 Financial Overview 71
8.4.3 Business Description 71
8.4.4 OAB Therapeutics Pipeline 73
8.5 Hisamitsu Pharmaceutical Co., Inc. 73
8.5.1 Company Overview 73
8.5.2 Financial Overview 73
8.5.3 OAB Therapeutics Pipeline 73
8.6 Teva Pharmaceutical Industries Limited 74
8.6.1 Company Overview 74
8.6.2 Financial Overview 74
8.6.3 Business Description 74
8.6.4 OAB Therapeutics Pipeline 76
8.6.5 Other Companies in the OAB Therapeutics Market 76

9 Overactive Bladder (OAB)Therapeutics - Licensing and Partnership Deals

10 Overactive Bladder (OAB) Therapeutics - Appendix
10.1 Definitions 81
10.2 Abbreviations 81
10.3 Methodology 82
10.3.1 Coverage 82
10.3.2 Secondary Research 83
10.3.3 Forecasting 83
10.3.4 Primary Research 85
10.3.5 Expert Panel Validation 86
10.4 Contact Us 86
10.5 Disclaimer 86
10.6 Bibliography 86

List of Tables

Table 1: OAB Therapeutics Market, Global, Revenue ($m), 2006–2011 15
Table 2: OAB Therapeutics Market, Global, Forecasts ($m), 2011–2019 18
Table 3: OAB Therapeutics Market, The US, Revenue ($m), 2006-2011 20
Table 4: OAB Therapeutics Market, The US, Forecasts ($m), 2011-2019 22
Table 5: OAB Therapeutics Market, France, Revenue ($m), 2006-2011 23
Table 6: OAB Therapeutics Market, France, Forecasts ($m), 2011-2019 25
Table 7: OAB Therapeutics Market, Germany, Revenue ($m), 2006-2011 26
Table 8: OAB Therapeutics Market, Germany, Forecasts ($m), 2011-2019 28
Table 9: OAB Therapeutics Market, Italy, Revenue ($m), 2006-2011 29
Table 10:OAB Therapeutics Market, Italy, Forecasts ($m), 2011-2019 31
Table 11: OAB Therapeutics Market, Spain, Revenue ($m), 2006-2011 32
Table 12: OAB Therapeutics Market, Spain, Forecasts ($m), 2011-2019 34
Table 13: OAB Therapeutics Market, The UK, Revenue ($m), 2006-2011 35
Table 14: OAB Therapeutics Market, the UK, Forecasts ($m), 2011-2019 37
Table 15: OAB Therapeutics Market, Japan, Revenue ($m), 2006-2011 38
Table 16: OAB Therapeutics Market, Japan, Forecasts ($m), 2011-2019 40
Table 17: Clinical Study Details of Detrol LA 47
Table 18: Clinical Study Details of Ditropan XL 48
Table 19: Clinical Study Details of Enablex, 2011 49
Table 20: Clinical Study Details of Toviaz, 2011 51
Table 21: OAB Therapeutics – Pre-registration Pipeline, 2011 54
Table 22: OAB Therapeutics – Phase III Pipeline, 2011 54
Table 23: OAB Therapeutics – Phase II Pipeline, 2011 55
Table 24: OAB Therapeutics – Phase I Pipeline, 2011 55
Table 25: OAB Therapeutics – Preclinical Pipeline, 2011 56
Table 26: OAB Therapeutics – Promising Drugs Under Clinical Development, 2011 59
Table 27: OAB Therapeutics – Clinical Trials by Country, 2011 62
Table 28: OAB Therapeutics – Clinical Trials by Phase, 2011 63
Table 29: OAB Therapeutics – Clinical Trials by Status, 2011 64
Table 30: OAB Therapeutics – Overall Sponsors, 2011 65
Table 31: OAB Therapeutics – Prominent Sponsors, 2011 66
Table 32: OAB Therapeutics - Top Companies Participating in Therapeutics Clinical Trials, 2011 67
Table 33: Allergan, Inc. – OAB Therapeutics Pipeline, September  2011 70
Table 34: Antares Pharma, Inc.–  OAB Therapeutics Pipeline, September  2011 71
Table 35: Astellas Pharma Inc.– OAB Therapeutics Pipeline , September 2011 73
Table 36: Hisamitsu Pharmaceutical Co., Inc., – OAB Therapeutics Pipeline , September 2011 73
Table 37: Teva Pharmaceutical Industries Limited – OAB Therapeutics Pipeline , September 2011 76
Table 38: OAB Therapeutics market – Other Future Players, 2011 76
Table 39: OAB Therapeutics, Global, Deals, 2011 79

List of Figures

Figure 1: Bladder Contraction and Relaxation: Nerve Impulses 9
Figure 2: Algorithm for the Treatment and Management of OAB 12
Figure 3: OAB Therapeutics Market, Global, Revenue ($m), 2006–2011 15
Figure 4: OAB Therapeutics, Market Share ($m, %), 2011 16
Figure 5: OAB Therapeutics Market, Global, Forecasts ($m), 2011–2019 18
Figure 6: OAB Therapeutics, Market Share ($m, %), 2019 19
Figure 7: OAB Therapeutics Market, The US, Revenue ($m), 2006-2011 20
Figure 8: OAB Therapeutics Market, The US, Forecasts ($m), 2011-2019 21
Figure 9: OAB Therapeutics Market, France, Revenue ($m), 2006-2011 23
Figure 10: OAB Therapeutics Market, France, Forecast ($m), 2011-2019 24
Figure 11: OAB Therapeutics Market, Germany , Revenue ($m), 2006-2011 26
Figure 12: OAB Therapeutics Market, Germany , Forecast ($m), 2011-2019 27
Figure 13: OAB Therapeutics Market, Italy, Revenue ($m), 2006-2011 29
Figure 14: OAB Therapeutics Market, Italy, Forecast ($m), 2011-2019 30
Figure 15: OAB Therapeutics Market, Spain, Revenue ($m), 2006-2011 32
Figure 16: OAB Therapeutics Market, Spain, Forecast ($m), 2011-2019 33
Figure 17: OAB Therapeutics Market, The UK, Revenue ($m), 2006-2011 35
Figure 18: OAB Therapeutics Market, The UK, Forecast ($m), 2011-2019 36
Figure 19: OAB Therapeutics Market, Japan, Revenue ($m), 2006-2011 38
Figure 20: OAB Therapeutics Market, Japan, Forecast ($m), 2011-2019 39
Figure 21: OAB Therapeutics, Key Events Impacting the Future Market, 2011 41
Figure 22: Opportunity and Unmet Need in the OAB Therapeutics Market, 2011 42
Figure 23: Strategic Competitor Assessment of the Major Marketed Products for OAB, 2011 45
Figure 24: OAB Therapeutics Pipeline by Phase of Development, 2011 53
Figure 25: OAB Therapeutics Market – Clinical Pipeline by Mechanism Of Action, 2011 56
Figure 26: Technology Trends Analytical Framework, 2011 57
Figure 27: Technology Trends Analytical Framework - Description, 2011 58
Figure 28: OAB Therapeutics – Clinical Trials by Country, 2011 62
Figure 29: OAB Therapeutics – Clinical Trials by Phase, 2011 63
Figure 30: OAB Therapeutics – Clinical Trials by Status, 2011 64
Figure 31: OAB Therapeutics - Overall Sponsors, 2011 65
Figure 32: OAB Therapeutics – Prominent Sponsors, 2011 66
Figure 33: OAB Therapeutics – Top Companies Participating in Therapeutics Clinical Trials, 2011 67
Figure 34: OAB Therapeutics, Strategic Assessment, 2011 68
Figure 35: OAB Therapeutics Market – Clinical Pipeline by Company , 2011 69
Figure 36: GlobalData Market Forecasting Model 85